Tags

Type your tag names separated by a space and hit enter

Aripiprazole for maladaptive behavior in pervasive developmental disorders.
J Child Adolesc Psychopharmacol. 2004 Fall; 14(3):455-63.JC

Abstract

OBJECTIVE

The aim of this study was to obtain preliminary data regarding the effectiveness and tolerability of aripiprazole in the treatment of children and adolescents with a pervasive developmental disorder (PDD).

METHOD

Five youths (mean age, 12.2 years; range, 5-18 years) meeting Diagnostic and Statistical Manual of Mental Disorders-Fourth Edition (DSM-IV) criteria for a PDD received a naturalistic, open-label trial of aripiprazole (mean dosage, 12.0 mg/day; range, 10-15 mg/day) for a minimum of 8 weeks (mean duration, 12 weeks; range, 8-16 weeks).

RESULTS

All 5 patients were judged to be responders, as determined by a Clinical Global Impressions-Improvement (CGI-I) scale rating of "much improved" or "very much improved." Aripiprazole was well tolerated. No extrapyramidal symptoms or clinically significant changes in heart rate or blood pressure occurred during the short-term trials. Two of 5 patients experienced mild somnolence. Two subjects lost weight, 2 subjects had no change, and 1 subject gained weight (mean change, -8.2 lbs; range, -30 to +1 lb). The weight loss was likely the result of the discontinuation of atypical antipsychotics that had led to significant weight gain.

CONCLUSIONS

This case series describes the effectiveness of aripiprazole in the treatment of maladaptive behaviors in 5 patients with a PDD. No significant adverse effects emerged during these short-term trials. Additional research is needed to support these preliminary findings.

Authors+Show Affiliations

Department of Psychiatry, Indiana University School of Medicine and the James Whitcomb Riley Hospital for Children, Indianapolis, IN 46202, USA.No affiliation info availableNo affiliation info available

Pub Type(s)

Case Reports
Journal Article
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.

Language

eng

PubMed ID

15650503

Citation

Stigler, Kimberly A., et al. "Aripiprazole for Maladaptive Behavior in Pervasive Developmental Disorders." Journal of Child and Adolescent Psychopharmacology, vol. 14, no. 3, 2004, pp. 455-63.
Stigler KA, Posey DJ, McDougle CJ. Aripiprazole for maladaptive behavior in pervasive developmental disorders. J Child Adolesc Psychopharmacol. 2004;14(3):455-63.
Stigler, K. A., Posey, D. J., & McDougle, C. J. (2004). Aripiprazole for maladaptive behavior in pervasive developmental disorders. Journal of Child and Adolescent Psychopharmacology, 14(3), 455-63.
Stigler KA, Posey DJ, McDougle CJ. Aripiprazole for Maladaptive Behavior in Pervasive Developmental Disorders. J Child Adolesc Psychopharmacol. 2004;14(3):455-63. PubMed PMID: 15650503.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Aripiprazole for maladaptive behavior in pervasive developmental disorders. AU - Stigler,Kimberly A, AU - Posey,David J, AU - McDougle,Christopher J, PY - 2005/1/15/pubmed PY - 2005/2/16/medline PY - 2005/1/15/entrez SP - 455 EP - 63 JF - Journal of child and adolescent psychopharmacology JO - J Child Adolesc Psychopharmacol VL - 14 IS - 3 N2 - OBJECTIVE: The aim of this study was to obtain preliminary data regarding the effectiveness and tolerability of aripiprazole in the treatment of children and adolescents with a pervasive developmental disorder (PDD). METHOD: Five youths (mean age, 12.2 years; range, 5-18 years) meeting Diagnostic and Statistical Manual of Mental Disorders-Fourth Edition (DSM-IV) criteria for a PDD received a naturalistic, open-label trial of aripiprazole (mean dosage, 12.0 mg/day; range, 10-15 mg/day) for a minimum of 8 weeks (mean duration, 12 weeks; range, 8-16 weeks). RESULTS: All 5 patients were judged to be responders, as determined by a Clinical Global Impressions-Improvement (CGI-I) scale rating of "much improved" or "very much improved." Aripiprazole was well tolerated. No extrapyramidal symptoms or clinically significant changes in heart rate or blood pressure occurred during the short-term trials. Two of 5 patients experienced mild somnolence. Two subjects lost weight, 2 subjects had no change, and 1 subject gained weight (mean change, -8.2 lbs; range, -30 to +1 lb). The weight loss was likely the result of the discontinuation of atypical antipsychotics that had led to significant weight gain. CONCLUSIONS: This case series describes the effectiveness of aripiprazole in the treatment of maladaptive behaviors in 5 patients with a PDD. No significant adverse effects emerged during these short-term trials. Additional research is needed to support these preliminary findings. SN - 1044-5463 UR - https://www.unboundmedicine.com/medline/citation/15650503/Aripiprazole_for_maladaptive_behavior_in_pervasive_developmental_disorders_ L2 - https://www.liebertpub.com/doi/full/10.1089/cap.2004.14.455?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -